Reference: VigiAccess. (2021). VigiAccess™. Retrieved from https://who-umc.org Summary: VigiAccess provides a comprehensive overview of adverse drug reactions (ADRs) associated with Covid-19 vaccines, highlighting a total of 2,183,912 reports. The data illustrates the geographical distribution of ADRs, with significant counts reported across continents such as the Americas, Europe, and Asia. The analysis categorises ADRs into various […]
Reference: Nakagami, H. (2021). Development of COVID-19 vaccines utilizing gene therapy technology. International Immunology, 33(10), 521–527. https://doi.org/10.1093/intimm/dxab013 Summary: The article discusses the urgent development of COVID-19 vaccines in response to the SARS-CoV-2 outbreak. Various vaccine technologies are being explored, categorised into four main groups: intact target viruses, proteins, viral vectors, and nucleic acids. RNA and
Reference: Seneff, S., & Nigh, G. (2021). Worse than the disease? Reviewing some possible unintended consequences of the mRNA vaccines against COVID-19. International Journal of Vaccine Theory, Practice, and Research, 2(1), 38-58. Summary: The article by Seneff and Nigh reviews the mRNA vaccines developed for COVID-19, primarily focusing on the Pfizer and Moderna vaccines. While
Reference: Centres for Disease Control and Prevention. (2021, March 4). Understanding mRNA COVID-19 vaccines. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html Summary: mRNA vaccines represent a novel approach to immunisation against infectious diseases, including COVID-19. They work by instructing cells to produce a harmless piece of the virus’s spike protein, eliciting an immune response without introducing the live virus. This process
Reference: FDA. (2021). Vaccines and related biological products advisory committee meeting: February 26, 2021. Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. FDA Briefing Document. Summary: The FDA briefing document details the Emergency Use Authorization (EUA) request submitted by Janssen Biotech for the Ad26.COV2.S vaccine aimed at preventing COVID-19. This single-dose adenovirus vector vaccine demonstrated
Reference: Author. (2021). Case investigation form for AEFI serious, severe, cluster, AESI for all vaccines including COVID-19. Retrieved from [insert URL if available] Summary: The document is a Case Investigation Form designed to report Adverse Events Following Immunisation (AEFI) and Adverse Events of Special Interest (AESI) for all vaccines, including COVID-19. It is intended for
Reference: Law, B. (2020). Priority List of COVID-19 Adverse Events of Special Interest: Quarterly Update December 2020. Safety Platform for Emergency Vaccines (SPEAC). Summary: The report provides a quarterly update on the Safety Platform for Emergency Vaccines (SPEAC) regarding Adverse Events of Special Interest (AESI) related to COVID-19. The December 2020 update includes three new
Reference: Wu, Q., Dudley, M. Z., Chen, X., Bai, X., Dong, K., Zhuang, T., Salmon, D., & Yu, H. (2021). Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Medicine, 19, 173. https://doi.org/10.1186/s12916-021-02059-5 Summary: This article presents a rapid review and meta-analysis of the safety profiles of COVID-19 vaccines. It highlights public
Reference: Thomas, S. J., Moreira, E. D. Jr., Kitchin, N., et al. (2021). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine, 385, 1761-73. https://doi.org/10.1056/NEJMoa2110345 Summary: This supplementary appendix provides detailed data related to the safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine, as explored in
Reference: Kirsch, S. (2021). All you need to know about COVID vaccine safety. COVID-19 Early Treatment Fund. Summary: Steve Kirsch, Executive Director of the COVID-19 Early Treatment Fund, argues that COVID vaccines may be responsible for more deaths than they prevent. He estimates over 150,000 excess deaths associated with the vaccines, contrasting this figure with